

PRESS RELEASE

+44 131 220 5355
admin@kynostx.com
kynostx.com

Kynos Therapeutics announces the expansion of its leadership team with the appointment of Jonathan Savidge as CEO

Edinburgh UK, 11 November 2022 - Kynos Therapeutics Ltd, an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today announced the appointment Dr Jonathan Savidge as CEO. The appointment is part of the next stage in the development of the company as it moves novel KMO inhibitors into clinical development. Jonathan brings a wealth of experience in fundraising and business and corporate development, having previously been founding CEO of Syndesi Therapeutics and concluding an acquisition deal earlier this year with a headline value of \$1BN.

Jonathan joins the Kynos Therapeutics leadership team comprising the founders, Professors Damian Mole and Scott Webster and CFO Alison Strutt. Professor Mole, founding CEO, will continue to play a key role in the company as scientific expert and champion, assuming the title of Chief Scientific Officer. Professor Webster will continue to oversee the development of molecules into the clinic as Chief Technology Officer.

Commenting on his appointment as CEO, Jonathan Savidge said "I am thrilled to join the team at Kynos at this exciting time as the company prepares to move into clinical development. The Kynos founders have built a world-leading expertise in the KMO target with a lead molecule poised to enter the clinic. I look forward to working with them, the rest of the Kynos team and the Board to progress development of these innovative KMO inhibitors and evolve the company to its next stage."

Kynos Therapeutics founder and CSO Damian Mole said "I am delighted to welcome Jonathan to the company. His track record and complementary skill set significantly strengthens the existing Kynos leadership team and will accelerate the development of the company and its KMO platform."

PRESS RELEASE

+44 131 220 5355
admin@kynostx.com
kynostx.com

About Kynos Therapeutics – www.kynostx.com

Kynos Therapeutics is developing an innovative portfolio of first-in-class medicines where there is an unmet medical need for new therapies. It is a spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism. Its innovative pipeline of first-in-class KMO inhibitors across key indications in inflammation, immunity and metabolism, was originally co-developed through a collaboration between GSK and the University of Edinburgh and is now exclusively licensed to Kynos.

Based in Edinburgh, UK, the company is financed by equity investment from Epidarex Capital, IP Group plc and Scottish Enterprise as well as a grant from Innovate UK.

Follow us on [LinkedIn](#)

For further information please contact:

At the Company

Jonathan Savidge, CEO, Kynos Therapeutics

E: admin@kynostx.com

